Profile data is unavailable for this security.
About the company
BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics, develops medicines in immuno-oncology. The Company’s most advanced neuroscience candidate, BXCL501, is an investigational, proprietary, orally dissolving film formulation of Dex in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimers disease in the at-home setting and in care facilities. Its most advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.
- Revenue in USD (TTM)1.38m
- Net income in USD-179.05m
- Incorporated2017
- Employees74.00
- LocationBioXcel Therapeutics Inc555 Long Wharf DrNEW HAVEN 06511-6107United StatesUSA
- Phone+1 (203) 643-8060
- Fax+1 (302) 636-5454
- Websitehttps://www.bioxceltherapeutics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Marinus Pharmaceuticals Inc | 30.99m | -141.41m | 82.95m | 165.00 | -- | 4.92 | -- | 2.68 | -2.63 | -2.63 | 0.5766 | 0.3072 | 0.144 | 1.55 | 6.11 | 187,812.10 | -65.70 | -49.64 | -77.53 | -57.76 | 93.76 | -- | -456.31 | -518.96 | 4.01 | -14.97 | 0.8132 | -- | 21.63 | -- | -613.59 | -- | 7.47 | -- |
LifeVantage Corp | 205.45m | 3.60m | 83.44m | 248.00 | 23.31 | 3.11 | 11.47 | 0.4061 | 0.2818 | 0.2818 | 16.01 | 2.11 | 3.20 | 2.53 | 91.56 | 828,443.60 | 5.60 | 11.65 | 8.51 | 18.92 | 79.32 | 82.20 | 1.75 | 3.42 | 1.01 | -- | 0.00 | 5.23 | 3.41 | 0.9838 | -18.59 | -18.77 | -7.98 | -- |
Chimerix Inc | 41.00k | -82.59m | 85.41m | 72.00 | -- | 0.4906 | -- | 2,083.13 | -0.9296 | -0.9296 | 0.0005 | 1.94 | 0.0002 | -- | 0.1226 | 569.44 | -36.50 | -30.45 | -39.59 | -34.09 | 100.00 | -- | -201,443.90 | -442.93 | -- | -- | 0.00 | -- | -99.04 | -46.24 | -147.68 | -- | -13.24 | -- |
MDxHealth SA - ADR | -100.00bn | -100.00bn | 85.68m | 258.00 | -- | 11.89 | -- | -- | -- | -- | -- | 0.2641 | -- | -- | -- | -- | -- | -51.62 | -- | -64.72 | -- | 50.90 | -- | -117.64 | 1.81 | -- | 0.8513 | -- | 89.43 | 19.84 | 2.14 | -- | 30.13 | -- |
BioXcel Therapeutics Inc | 1.38m | -179.05m | 85.93m | 74.00 | -- | -- | -- | 62.27 | -6.16 | -6.16 | 0.0474 | -1.89 | 0.0099 | 0.6343 | 8.65 | 18,648.65 | -128.10 | -74.57 | -163.23 | -84.06 | 8.62 | -- | -12,974.86 | -32,300.74 | 2.57 | -21.87 | 2.28 | -- | 268.00 | -- | -8.02 | -- | -43.26 | -- |
Beyondspring Inc | 1.75m | -21.03m | 87.58m | 35.00 | -- | -- | -- | 50.02 | -0.5392 | -0.5392 | 0.0449 | -0.6868 | 0.0493 | -- | -- | 48,638.89 | -61.80 | -75.50 | -88.85 | -96.48 | -- | -- | -1,253.46 | -4,977.12 | -- | -- | -- | -- | 29.61 | -- | 36.82 | -- | -13.54 | -- |
Connect Biopharma Holdings Ltd (ADR) | 0.00 | -59.50m | 87.61m | 81.00 | -- | 0.905 | -- | -- | -1.08 | -1.08 | 0.00 | 1.76 | -- | -- | -- | 0.00 | -- | -66.24 | -- | -71.36 | -- | -- | -- | -- | -- | -- | 0.0046 | -- | -- | -- | 49.61 | -- | 10.32 | -- |
Jaguar Health Inc | 9.76m | -41.30m | 87.84m | 49.00 | -- | 4.71 | -- | 9.00 | -3.64 | -3.64 | 0.4239 | 0.0676 | 0.1988 | 0.2513 | 5.08 | 199,204.10 | -85.33 | -95.29 | -153.34 | -163.54 | 79.13 | 67.28 | -429.27 | -522.28 | 1.34 | -2.95 | 0.8799 | -- | -18.36 | 17.19 | 12.97 | -- | -- | -- |
Spero Therapeutics Inc | 103.78m | 22.81m | 87.85m | 46.00 | 4.02 | 0.8082 | 3.79 | 0.8465 | 0.4055 | 0.4055 | 1.96 | 2.02 | 0.6757 | -- | 4.01 | 2,256,087.00 | 14.85 | -35.52 | 18.36 | -41.75 | -- | -- | 21.98 | -124.40 | -- | -- | 0.00 | -- | 93.95 | 92.11 | 149.14 | -- | -- | -- |
CEL-SCI Corp | 0.00 | -31.05m | 87.99m | 43.00 | -- | 6.44 | -- | -- | -0.6825 | -0.6825 | 0.00 | 0.2529 | 0.00 | -- | -- | -- | -84.76 | -70.19 | -97.55 | -78.31 | -- | -- | -- | -15,434.15 | 0.7822 | -42.08 | 0.4717 | -- | -- | -- | 13.99 | -- | 223.59 | -- |
Holder | Shares | % Held |
---|---|---|
Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 2.52m | 7.49% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 1.28m | 3.80% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 1.05m | 3.12% |
Columbia Management Investment Advisers LLCas of 31 Dec 2023 | 541.06k | 1.61% |
Adage Capital Management LPas of 31 Dec 2023 | 465.38k | 1.38% |
Geode Capital Management LLCas of 31 Dec 2023 | 450.23k | 1.34% |
SSgA Funds Management, Inc.as of 31 Dec 2023 | 440.33k | 1.31% |
Beacon Pointe Advisors LLCas of 31 Dec 2023 | 301.74k | 0.90% |
Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2023 | 225.39k | 0.67% |
Charles Schwab Investment Management, Inc.as of 31 Dec 2023 | 187.51k | 0.56% |